Hypermed Inc. Uses of U.S.-Patented safe Hyperthermia Technology to

Treat Cancers and AIDS&

Background Science & Published Academic Papers

US National Cancer Institute Info on Hyperthermia in cancer treatment

Why Hyperthermia?

Cancer cells and viruses can be significantly reduced by heat, as in hyperthermia treatment. This is a well-known biological fact.

What has held back the use of hyperthermia to treat cancer and viral infections such as AIDS is the risk of damage to the brain.

Hypermed, Inc. has developed a patented technology to protect the brain to enable using hyperthermia to be used safely in treating cancers, AIDS and other infections.

Hypermed Inc. Has U.S. Patent on Brain Protection

Patent #6669661: “Method and Device for Central Nervous System Protection During Whole Body Hyperthermia or Hypothermia”, Inventor: Dr. Thomas Yee, MD

Established science: Heat can kill cancer cells & viruses (HIV).

Established science: Hypothermia can preserve viability of organs.

Up to now, whole-body hyperthermia is not used due to fear of brain damage

This patented technology makes it safe to perform whole-body profound hyperthermia to cure cancer and to cure infections such as AIDS.

Market & Revenue Projection for Treating Cancers with Hyperthermia

500,000 people die from cancer every year in the U.S. 1,000,000 more people die in other affluent countries.

Heat can kill cancer cells.

Hypermed, Inc. has patented technology enabling safe whole-body hyperthermia used in conjunction with chemo, radiation, immuno-therapy, angiogenesis-inhibiting treatments to cure cancers.

If only 10% of those dying of cancer in affluent world seek Hyperthermia treatment, at $50,000, the potential annual revenue is 7.5 Billion Dollars.

Market & Revenue Projection for Using Safe Whole-Body Hyperthermia to Treat AIDS & other Infections

In the US , there are more than 2 million people with HIV virus & AIDS. World-wide, more than 8 million people have HIV infection. Millions of people die from flu & other infections yearly.

Heat can kill HIV, other viruses, and bacteria. Hypermed, Inc. has the US Patent that enables safe administration of whole body hyperthermia.

If only 100,000 people per year seek Hyperthermia treatment for AIDS and other infections, at $50,000, potential annual revenue is $5 Billion Dollars.

Venture Capital Funding Needed for our Safe Whole-Body Hyperthermia Technology

To demonstrate the safety profile and efficacy of hyperthermia treatment, Hypermed seeks 5 million dollars to complete animal study in the U.S. and human study abroad.

1st Stage: Animal study using pigs at Utah Artificial Heart Institute

Subjects: 60 pigsTime: 6 monthsCost: 2 million dollars

2nd Stage: Human study on young AIDS patients in Asia Subjects: 50 young men with AIDS

Time: 6 monthsCost: 3 million dollars

Patent & Key Technology Abstract A method and device for intentionally inducing whole-body

hyperthermia or hypothermia in a patient for medical treatment while protecting the central nervous system from damage

A whole-body immersion chamber for temperature alteration. And novel uses of existing FDA-approved pharmaceutical agents and monitors to achieve profound brain metabolism reduction and protection prior to temperature alteration or rapid detox challenge

The patient's cerebral spinal fluid is circulated and maintained at temperatures less drastically altered from normal temperatures by a pump and a heater and cooler connected to the patient's spine through catheters.

The patient's central nervous system blood is separated from the rest of the circulatory system and circulated and maintained at temperatures less drastically altered from normal temperatures by pumps and a heater and cooler. The remaining blood in the patient's body is circulated and temperature controlled through pumps and a heater and cooler.

Sites of Animal Research

UCSD Animal Research

FacilityUniversity of California, San Diego

La Jolla, California

Utah Artificial Heart InstituteSalk Lake City, Utah

Development site of the Jarvik Artificial Heart

Published Journal Articles

Supporting Hypermed Inc.’s Basis for Developing Technology in

Rapid Detox and in Hyperthermia Treatment for Cancer

Supporting Published Journal Papers on

Hyperthermia:Medical Journal: Annals of Oncology. 2002 Aug;13(8):1173-84.

Heating the patient: a promising approach?

van der Zee J.Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of Radiation Oncology, Hyperthermia Unit, Rotterdam, The Netherlands

The effects of both radiotherapy and many drugs are enhanced at an increased temperature

These findings justify using hyperthermia as part of standard treatment in tumor sites for which its efficacy has been proven and, furthermore, to initiate new studies with other tumors. Hyperthermia is certainly a promising approach and deserves more attention than it has received until now.

US National Cancer Institute Info

Medical Journal: Perfusion. 2002 Jul;17(4):279-90.

Whole-body hyperthermia: a review of theory, design and application.

Vertree RA, Leeth A, Girouard M, Roach JD, Zwischenberger JB.Department of Surgery,

The University of Texas Medical Branch, Galveston

All patients were safely heated to 42 or 42.5 degrees C for 2 h and survived the 30-day study period

Hyperthermia has been used successfully to treat isolated neoplastic lesions of the head and neck, regional tumors such as melanoma of the limb, and is under investigation as either an adjunct to, or therapy for, locally disseminated and systemic diseases

Surgery. 2002 Jan;131(1 Suppl):S121-7.

Hyperthermia for rectal cancer.

Ohno S, Sumiyoshi Y, Mori M, Sugimachi K.

Department of Breast Surgery, National Kyushu Cancer Center, Fukuoka, Japan.

Hyperthermia combined with radiation or chemotherapy demonstrates great promise for the treatment of patients with carcinoma of the rectum.

Cancer Immunology and Immunotherapy. 2002 Dec;51(11-12):603-13.

41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell

activation in patients with various malignant diseases.

Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-Becker S Department of Oncology and Hematology, University Clinic Eppendorf, Hamburg, Germany

This the first study to provide evidence for prolonged WBH-CT-induced activation of human T cells.

Whole body hyperthermia (WBH) has been used as an adjunct to radio-/chemotherapy in patients with various malignant diseases

Critical Review of Oncology and Hematology. 2002 Jul;43(1):33-56.

The cellular and molecular basis of hyperthermia. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R,

Medical Clinic, Department of Hematology and Oncology, Charite Medical School, Humboldt-University, Campus Virchow Clinic, D-13344 Berlin, Germany.

An improvement of both local control and survival rates have been demonstrated by adding local/regional hyperthermia to radiotherapy in patients with locally advanced or recurrent superficial and pelvic tumors

European Journal of Cancer. 2001 Jul;37(11):1429-34.

Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild

hyperthermia.

Saga T, Sakahara H, Nakamoto Y, Sato N, Ishimori T, Mamede M, Kobayashi H, Masunaga S, Sasai K, Kuroki M, Konishi J.

Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto, Japan.

The addition of whole-body mild hyperthermia significantly enhanced the therapeutic effect of radio-immunotherapy by increasing the radiosensitivity of the tumor.

International Journal of Hyperthermia. 2003 Jul-Aug;19(4):444-60.

Heat- and 4-hydroperoxy-ifosfamide-induced apoptosis in B cell precursor leukaemias.

Mauz-Korholz C, Dietzsch S, Banning U, Trobs RB, Korholz D.Department of Pediatrics, University of Leipzig Medical Center, Oststr 21-25, D-04317 Leipzig, Germany

Application of hyperthermia enhances efficacy of certain anti-neoplastic drugs such as ifosfamide

whole body thermochemotherapy could be considered as a treatment option in relapsed leukaemic patients.

Cancer Immunology and Immunotherapy. 2002 Dec;51(11-12):603-13.

41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in

patients with various malignant diseases.

Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-Becker S Department of Oncology and Hematology, University Clinic Eppendorf, Hamburg, Germany

This the first study to provide evidence for prolonged WBH-CT-induced activation of human T cells.

Whole body hyperthermia (WBH) has been used as an adjunct to radio-/chemotherapy in patients with various malignant diseases